Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Analytical performance goals for measuring prostate-specific antigen

H A Fritsche1, R J Babaian

  • 1Department of Laboratory Medicine, University of Texas M. D. Anderson Cancer Center, Houston 77030.

Clinical Chemistry
|July 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system.

International journal of cancer·2011
Same author

Technical validation of an autoantibody test for lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

Five-year stability study of free and total prostate-specific antigen concentrations in serum specimens collected and stored at -70 degrees C or less.

The International journal of biological markers·2007
Same author

Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance.

The Journal of urology·2007
Same author

Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer.

International journal of radiation oncology, biology, physics·2003
Same author

Sural nerve graft during non-nerve-sparing radical retropubic prostatectomy restores erectile function in patients with locally advanced prostate cancer.

Prostate cancer and prostatic diseases·2002
Same journal

Comparison of Information-Dependent Acquisition and Sequential Window Acquisition of All Theoretical Mass Spectra for Untargeted Drug Testing on a Linear Ion Trap-Pulsing Quadrupole-Time of Flight Mass Spectrometer.

Clinical chemistry·2026
Same journal

Patterns of One-Year Change in HbA1c and Continuous Glucose Monitoring (CGM) Metrics in Older Adults with Type 2 Diabetes.

Clinical chemistry·2026
Same journal

TSH Pediatric Reference Intervals: Lack of CALIPER Applicability to US-Based Populations.

Clinical chemistry·2026
Same journal

Rapid Detection of Hemoglobinopathy Variants Using One-Step Library Preparation and Nanopore Sequencing.

Clinical chemistry·2026
Same journal

Editor's Note: Circulating Proteolytic Products of Carboxypeptidase N for Early Detection of Breast Cancer.

Clinical chemistry·2026
Same journal

In Reply to Reflexing NT-proBNP for sFlt-1/PlGF Ratios That Fall into the Measurement Uncertainty for Preeclampsia Risk Classification.

Clinical chemistry·2026
See all related articles

Establishing biologically-based performance criteria for prostate-specific antigen (PSA) testing is feasible. Current immunoassay technology meets these goals, but future applications may require enhanced analytical performance for tumor marker tests.

Area of Science:

  • Clinical Chemistry
  • Biomarker Analysis
  • Medical Diagnostics

Background:

  • Prostate-specific antigen (PSA) is a key biomarker for prostate cancer management.
  • Evaluating the analytical performance of PSA tests is crucial for reliable clinical decision-making.
  • Existing evaluation methods may not fully capture the biological variability of PSA.

Purpose of the Study:

  • To assess the feasibility of using fixed-limit criteria for PSA test performance evaluation.
  • To establish performance goals based on medical relevance and biological variation.
  • To determine if current immunoassay technology can meet these goals.

Main Methods:

  • Utilized fixed-limit criteria incorporating medical relevance and biological variation.
  • Estimated within-subject variation of serum PSA at clinical decision points.

Related Experiment Videos

  • Calculated coefficient of variation (CV) performance goals.

    • Main Results:

    • Within-subject variation for serum PSA is approximately 10-20% at clinical decision points.
    • Performance goals of 5-10% CV are achievable with current immunoassay technology.
    • These goals align with precision requirements derived from clinical experience and use.

    Conclusions:

    • Biologically-based fixed-limit criteria are feasible and necessary for PSA testing.
    • Current technology can meet established performance goals for existing PSA applications.
    • Emerging clinical uses of PSA may necessitate advancements in analytical performance.